



HAL
open science

Effect of amphotericin B on the infection success of *Schistosoma mansoni* in *Biomphalaria glabrata*.

Yves Moné, Guillaume Mitta, David Duval, Benjamin E F Gourbal

► **To cite this version:**

Yves Moné, Guillaume Mitta, David Duval, Benjamin E F Gourbal. Effect of amphotericin B on the infection success of *Schistosoma mansoni* in *Biomphalaria glabrata*.. *Experimental Parasitology*, 2010, 125 (2), pp.70-5. 10.1016/j.exppara.2009.12.024 . halsde-00495366

HAL Id: halsde-00495366

<https://hal.science/halsde-00495366v1>

Submitted on 25 Jun 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Effect of amphotericin B on the infection success of *Schistosoma mansoni* in *Biomphalaria***
2 ***glabrata*.**

3
4 Yves Moné, Guillaume Mitta, David Duval and Benjamin E.F. Gourbal[§].

5
6
7 Parasitologie Fonctionnelle et Evolutive, UMR 5244, CNRS, EPHE, UPVD, Biologie & Ecologie
8 Tropicale et Méditerranéenne, Université de Perpignan, 52 Ave Paul Alduy, 66860 Perpignan
9 Cedex, France

10

11

12

13

14

15 [§] Corresponding author: Benjamin Gourbal

16 *UMR 5244, CNRS Université de Perpignan,*

17 *52 Ave Paul Alduy, 66860 Perpignan Cedex, France*

18 Phone: 33 (0)4 30 19 23 12

19 Fax: 33 (0)4 68 66 22 81

20 e-mail: benjamin.gourbal@univ-perp.fr

21

22

23 ABSTRACT

24 In the present study, we examined the effect of amphotericin B on larval stages (miracidia and
25 primary sporocyst) of the helminth *Schistosoma mansoni*, the causative agent of human
26 schistosomiasis. Amphotericin B (AmB) is a polyene macrolide that disturbs the function of the cell
27 membrane; it is widely used as prophylactic antimycotic agent in *in vitro* culture. We show for the
28 first time that *S. mansoni* miracidia infectivity is considerably reduced after AmB treatment.
29 Moreover we demonstrate that AmB does not affect the development, growth, viability, and
30 behavior of miracidia and primary sporocysts. Our data indicate that AmB effects on *S. mansoni*
31 sporocyst prevalence are linked to the oxidative properties of AmB. These may alter the capacity of
32 sporocysts to respond to the oxidative stress generated by the snail immune defence system.

33

34 Keywords: Amphotericin B, *Schistosoma mansoni*, miracidium, *Biomphalaria glabrata*, reactive
35 oxygen species (ROS).

36

37 INTRODUCTION

38

39 Schistosomiasis or bilharzia is a tropical parasitic disease affecting 200 million humans in 74
40 countries, causing 200,000 deaths annually. It is the second most important tropical disease in terms
41 of morbidity after malaria. Schistosomiasis is caused by flatworms of the genus *Schistosoma*, with
42 the most common causative species being *S. haematobium*, *S. japonicum*, and *S. mansoni* (Chitsulo,
43 et al., 2004, Gryseels, et al., 2006).

44 The cycle of the parasite is complex. It requires humans as definitive host and certain freshwater
45 snail species as intermediate hosts. Infection occurs in water by the free-living larval stages
46 (cercaria for the definitive host and miracidia for the intermediate host). Significant attention has
47 been paid to freshwater snails over the past because of their both medical and epidemiological
48 importance as intermediate hosts for schistosome parasites. Moreover, the interaction between
49 *Schistosoma mansoni* and the snail *Biomphalaria glabrata* provides a model of choice in
50 evolutionary biology to investigate the host-parasite coevolutionary dynamics (Beltran and Boissier,
51 2008, Beltran, et al., 2008, Bouchut, et al., 2008, Roger, et al., 2008, Steinauer, 2009). In this
52 context, the *in vitro* maintenance of schistosome intramolluscan stages is a valuable tool to
53 investigate host-parasite interaction, particularly at the molecular level (Coustau and Yoshino,
54 2000). Thus, *in vitro* culture is used often in this model to obtain pure parasites and/or secretion
55 products to identify the molecules involved in host-parasite interplay (Bender, et al., 2002, Guillou,
56 et al., 2007, Roger, et al., 2008, Roger, et al., 2008), to perform pharmacological investigations
57 (Mattos, et al., 2006), or to study parasite development (Azzi, et al., 2009).

58 To avoid the risk of contamination in those *in vitro* culture, antimicrobial substances were widely
59 used, mainly streptomycin, penicillin (as antibiotics) and amphotericin B (as antimycotic) (Smyth,
60 1990). It is known that antimicrobials can have side effects and consequently may affect the
61 cultivated organisms (Kuhlmann, 1995). Moreover, recent work has demonstrated activity of AmB
62 against helminth parasites (Olds, et al., 1981, Reuter, et al., 2003).

63 In this paper we describe the effect of an antimicrobial mix on the miracidium infectivity. This
64 antimicrobial substance is a mixture of two antibiotics, penicillin (PnG) and streptomycin (StrS)
65 and one antimycotic: amphotericin B (AmB). Herein we show that AmB decreases the infectivity of
66 the miracidium, the snail infective larval stage of schistosome parasite. To understand this anti-
67 parasitic effect better, the mode of action of AmB was examined.

68

69 MATERIALS AND METHODS

70

71 *Biological material*

72 The host-parasite association *Biomphalaria glabrata* – *Schistosoma mansoni* originated from
73 Brazil, and has been maintained in the laboratory for several years. Miracidia from *S. mansoni* were
74 hatched from eggs axenically recovered from infected hamster (*Mesocricetus auratus*) livers after
75 50 days according as described procedures (Roger, et al., 2008). Briefly, livers were collected and
76 kept in sterile 0.85% saline, containing a 1X antibiotic/antimycotic mixture (100 units/ml penicillin
77 G, 0.1mg/ml streptomycin sulfate, 0.25µg/ml amphotericin B). The livers were homogenized and
78 the eggs were filtered, washed and transferred to natural mineral water (Volvic) to allow miracidia
79 to hatch under illumination.

80

81 *Effect of antimicrobial substances on S. mansoni miracidia infectivity*

82 Different antimicrobial substances were added directly into the dish containing the miracidia,
83 and they were incubated for 3 hours before snail infection. Five groups of miracidia were used: a
84 control group (untreated miracidia), an antibiotic/antimycotic (AM) mixture 1X treated group, a
85 penicillin G (PnG) treated group (100 units/ml), a streptomycin sulfate (StrS) treated group (0.1
86 mg/ml), a PnG (100 units/ml)/StrS (0.1 mg/ml) treated group, and an amphotericin B (AmB) treated
87 group (0.25 µg/ml). For each group, 20 snails (5-7 mm diameter) were exposed individually to 10

88 miracidia. Following exposure snails were kept in water at a constant temperature of 26°C and fed
89 on lettuce *ad libitum*.

90 The infected or non-infected status of the exposed snails was detected by the observation of the
91 mother sporocysts (Sp1) in the head-foot region. The snails were fixed 15 days post-exposure as
92 described (Theron, et al., 2008). Briefly, the snails were relaxed in water containing an excess of
93 crystalline menthol for 6 hours. The snail shell was removed and the body was fixed in modified
94 Raillet-Henry's solution (930 ml distilled water, 6g sodium chloride, 50ml formol 40%, 20 ml
95 acetic acid). The presence of Sp1 in each snail was determined by dissection of the head-foot zone
96 and visual inspection. The Sp1 were readily observable as translucent white bodies within an
97 opaque yellow tissue background.

98

99 *Effect of antimicrobial substances on S. mansoni miracidia swimming behaviour*

100 Four groups of miracidia were formed and incubated during 3 hours in Volvic water containing
101 different antimicrobial substances AM 1X, PnG (100 units/ml), StrS (0.1 mg/ml), and AmB (0.25
102 µg/ml). An additional control experiment was done with untreated miracidia. The miracidia were
103 filmed, their swimming behavior (sinuosity, rotation) was observed and their linear swimming
104 speed was determined using the video analysis software Kinovea (<http://www.kinovea.org>).

105

106 *Effect of antimicrobial substances on S. mansoni miracidia in vitro transformation to sporocysts* 107 *and sporocyst viability*

108 Miracidia were submitted to *in vitro* transformation to obtain primary sporocysts (Sp1).
109 Miracidia were cultured for 24 h in sterile Chernin's balanced salt solution (CBSS) (Chernin, 1963),
110 containing StrS (0.1 mg/ml) and PnG (100 units/ml) mixture (used as control), AM 1X, or AmB
111 (0.25 µg/ml). The experiments were conducted two times in triplicate on 24 well plates with 20
112 sporocysts per well.

113 The percentage of transformed miracidia was determined directly by the observation of remaining
114 miracidia not transformed after 24 hours of culture. The viability of the Sp1 was assessed by two
115 different methods: (i) Sp1 were observed with a light microscope and considered alive when their
116 motility and/or the beating of the flame cells' flagella was observed; (ii) the Sp1 were exposed to
117 trypan blue and observed using a light microscope. Sp1 were considered dead when intra-sporocyst
118 trypan blue accumulation could be observed.

119

120 *Effect of AmB on B. glabrata hemocyte Reactive Oxygen Species (ROS) production*

121 *Biomphalaria glabrata* hemocytes were recovered after hemolymph puncture as previously
122 described (Bouchut, et al., 2006). Briefly, for each testing condition 500 µl of hemolymph were
123 recovered and centrifuged (600g, 10 min) to pellet the hemocytes. Hemocytes were washed three
124 times in PBS (phosphate buffered saline) to remove hemoglobin. Hemocytes were then incubated in
125 500 µl of PBS (control), or PBS containing (i) 1µM Phorbol 12-Myristate 13-Acetate (PMA), (ii)
126 0.25µM AmB, (iii) 1µM PMA + 0.25µM AmB. After 4 hours 500 µl of Nitroblue tetrazolium
127 (NBT) was added to each sample and incubated at 20°C for 60 min. The four samples were then
128 centrifuged (600g, 10 min) and the hemocyte pellets were resuspended in 70% MeOH. Samples
129 were centrifuged (600g, 10 min), the supernatant was discarded, 200 µl of dimethylsulfoxide
130 (DMSO)/2 M KOH solution was added and samples were mixed vigorously. Absorbance of
131 supernatants was read in a spectrophotometer at 620 nm vs. a DMSO/KOH blank. For each
132 condition, values were expressed as OD for 5×10^4 hemocytes. The experiments were conducted two
133 times in triplicate for each sample. The ROS-mediated (Reactive Oxygen Species) reduction of
134 NBT results in the precipitation of insoluble blue formazan which can be quantified
135 spectrophotometrically in hemocytes or in hemocytes after treatment with the antimycotic AmB and
136 the respiratory burst stimulator PMA. This protocol was adapted from a published method
137 (Anderson and Brubacher, 1995).

138

139 *Effect of AmB on S. mansoni sporocysts resistance to oxidative stress*

140 Miracidia were cultured 24 h in sterile Chernin's balanced salt solution (CBSS), containing
141 StrS (0.1 mg/ml) and PnG (100 units/ml) mixture (used as control), or AmB (0.25 µg/ml). After 24
142 hours of culture, increasing amounts of H₂O₂ were added to the culture medium of primary
143 sporocysts (Sp1). Five concentrations of H₂O₂ were tested: 0, 200, 400, 800 and 1600 µM. After 4
144 hours, the viability of Sp1 was assessed as described above

145 The experiments were conducted two times in triplicate on 24 well plates with 20 sporocysts per
146 well.

147

148 *Effect of AmB on S. mansoni sporocysts total antioxidant capacity*

149 Quantitative measurement of the cumulative antioxidant capacity of sporocysts was determined
150 following exposition to different AmB concentrations. Total antioxidant activity was measured
151 using the Antioxidant Assay Kit (Sigma). For each test, 2000 sporocysts were *in-vitro* transformed
152 and cultured in sterile Chernin's balanced salt solution (CBSS), containing 0; 0.25; 0.5; or 1.25
153 µg/ml of AmB. After 24h fully transformed sporocysts were recovered by gentle centrifugation
154 (800g, 5 minutes, 4°C), sonicated (3 pulses of 20 seconds), centrifuged to pellet cell debris (12000g,
155 15 minutes, 4°C) and antioxidant capacity of supernatant was determined following manufacturer's
156 recommendations. Protein amount in the supernatant was determined using Bradford protein
157 quantification assay and used as a correcting factor. The experiment was done six times for each
158 AmB concentration tested.

159

160 *Statistical analysis*

161 Results of miracidia infection, miracidia transformation and sporocyst viability were analyzed
162 using a two-tailed Fisher's Exact test. Results of miracidia linear swimming speed and hemocyte
163 ROS production were analyzed using the Kruskal-Wallis test. Results of AmB effects on sporocysts

164 resistance to oxidative stress and antioxidant capacity were analyzed using the Student T test.
165 Levels of confidence lower than 0.05 were considered to be statistically significant.

166

167 RESULTS

168 *Effect of antimicrobial substances on S. mansoni miracidia infectivity*

169 We assayed the effect of miracidia treatment with antimicrobial substances on infectivity (
170 Fig. 1). Miracidia treated with 1X AM and AmB display significant prevalence decrease ($P < 0.006$
171 and $P < 0.005$ respectively) compared to the control. We observed a reduction of more than 50% of
172 *S. mansoni* miracidia infectivity after those two treatments. Prevalence for the control was 65% and
173 only 32.5% for 1X AM and 25% for AmB (Fig. 1). There is no significant difference between AM
174 1X and AmB treatments, and neither StrS nor PnG had effects on miracidia infectivity compared to
175 the control (Fig. 1). These results permit us to conclude that AmB is reducing *S. mansoni* miracidia
176 infectivity and that no synergistic or antagonistic effects could be observed with the other
177 antimicrobial substances tested here

178 *Effect of antimicrobial substances on S. mansoni miracidia swimming behavior*

179 Swimming behavior of miracidia was investigated after treatment with antimicrobial
180 substances. Linear swimming speed (Fig. 2A), sinuosity and miracidia swimming rotation (data not
181 show) did not differ from that of the control. The linear swimming speed was of 1.35, 1.18, 1.17,
182 1.21, and 1.16 mm/s for the control, 1X AM, AmB, PnG, and StrS respectively. No significant
183 differences were observed between those values (Kruskal-Wallis ; $P = 0.63$). Thus, none of the
184 molecules tested have an effect on swimming behavior of miracidia

185

186 *Effect of antimicrobial substances on S. mansoni miracidia in vitro transformation to sporocysts 187 and sporocysts viability*

188 In this experiment the use of antimicrobial molecules in the culture medium was necessary
189 to avoid microbial contamination. Thus, a PnG/StrS mixture was used as control. Miracidia

190 transformation and sporocyst viability was compared between this control and 1X AM or AmB (see
191 Fig. 2B). Miracidia transformation did not differ from that of the control. The percentage of
192 transformed miracidia to sporocysts was 97, 96 and 98% for the control, 1X AM, and AmB,
193 respectively. The sporocysts viability after 24 h in culture was very good with 93.2, 93.8, and
194 91.9% of live sporocysts for the control, 1X AM, and AmB (Fig. 2B.1). Miracidia and sporocysts
195 did not show any tegumental lysis or shape modifications when comparing the control and AmB
196 (Fig. 2B.2). Motility, beating of the flame cells' flagella or trypan blue efflux were the same for all
197 samples. To conclude, none of the molecules tested seem to have an effect on miracidia
198 transformation and sporocyst viability.

199

200 *Effect of AmB on B. glabrata hemocyte Reactive Oxygen Species (ROS) production*

201 Here we tried to quantify the ROS production of *B. glabrata* hemocytes after treatment with
202 AmB in the presence or absence of PMA, a respiratory burst stimulator. The ROS produced by the
203 hemocytes reduce NBT and the optical density (OD) of reduced NBT was quantified. Intracellular
204 ROS production by AmB-treated and PMA-stimulated cells did not differ from that of
205 untreated/unstimulated control cells (Fig. 2C). The OD of reduced NBT for 5×10^4 hemocytes was
206 0.084, 0.083, 0.088 and 0.095 for the control, PMA, AmB and AmB/PMA respectively (Fig. 2C).
207 No significant differences were observed between those values (Kruskal-Wallis ; $P=0.84$). It seems
208 that AmB did not affect *B. glabrata* hemocyte ROS production, with or without burst stimulation.

209

210 *Effect of AmB on S. mansoni sporocysts resistance to oxidative stress*

211 Resistance of Sp1 to oxidative stress was investigated after treatment with AmB. Here we
212 used exposure to H_2O_2 for 4 hours as oxidative stress. Different concentrations of H_2O_2 were used.
213 No significant differences between AmB-treated and untreated sporocysts (control) were observed
214 for 0, 200, 400 and 800 μM of H_2O_2 (Fig. 3). However, for 1600 μM a significant difference was
215 noted (Student T-test; $P=0.048$) (Fig. 3). Viability values were 95.5 and 99.3% for AmB-treated and

216 untreated, respectively. This suggests that Sp1 exposed to AmB would be less able to respond to
217 oxidative stress.

218

219 *Effect of AmB on S. mansoni sporocysts total antioxidant capacity*

220 Total antioxidant capacity of sporocysts was determined after exposition to increase concentrations
221 of AmB (Fig. 4). Sporocysts antioxidant activity decreases when AmB concentrations increase.
222 Antioxidant concentration was 214.02 μ M when no AmB was present in the culture medium and
223 significantly decreased to 105.08 μ M when 1.25 μ g/ml of AmB was added to the culture medium
224 (Student T-test; P=0.00107) (Fig. 4). To conclude it seems that AmB affect directly the total
225 antioxidant capacity of sporocysts.

226

227 DISCUSSION

228 AmB is known to be an antifungal agent that binds to sterols (cholesterol and ergosterol) in
229 the fungal cell wall, forming transmembrane channels resulting in osmotic lysis and death of the
230 organism (HsuChen and Feingold, 1973, HsuChen and Feingold, 1973, Reuter, et al., 2003). On the
231 other hand, several studies suggest that AmB has an effect on prokaryotes and eukaryotes
232 (protozoan and metazoan) (Cruz, et al., 1980, Lachaud, et al., 2009, Olds, et al., 1981, Reuter, et al.,
233 2003, Thomas, et al., 1973). The protective effect against those pathogens was linked mainly to
234 AmB immunomodulatory effects and induction of macrophage activation (Beccari, et al., 1991,
235 Kumar and Chakrabarti, 2000, Little, et al., 1978, Olds, et al., 1981, Wilson, et al., 1991, Wolf and
236 Massof, 1990). However on helminths AmB was shown to act by two different ways. Alveolar
237 echinococcosis caused by the parasitic cestode *Echinococcus multilocularis* was significantly
238 reduced by AmB treatment (Reuter, et al., 2003). AmB seems to act directly on the parasite cell
239 membrane. This destructive effect suppressed parasite growth and development (Reuter, et al.,
240 2003). With the helminth *S. mansoni*, AmB treatment increases resistance in mice to a challenge
241 with *S. mansoni* cercariae (Olds, et al., 1981). AmB treatment was effective in protecting mice by

242 killing schistosomula, the migrating larval stage of the parasite. This study demonstrated activation
243 of murine macrophages by AmB, which contributes to enhanced mice resistance to infection (Olds,
244 et al., 1981).

245 In our study we investigated the effect of AmB on the *S. mansoni* larval stage interacting
246 with the invertebrate host *B. glabrata*. To our knowledge, we demonstrate for the first time a
247 reduction of *S. mansoni* miracidia infectivity after AmB treatment (Fig. 1). We observed a reduction
248 of Sp1 prevalence of more than 50% after treatment of miracidia with AmB (Fig. 1).

249 Based on previous work conducted on the AmB effect on helminthes, we tried to determine the
250 mechanisms by which AmB reduces *S. mansoni* miracidia infectivity. A direct deleterious effect on
251 miracidia was considered. We investigated the effect of AmB on parasite and host behavior and
252 physiological traits but no significant differences were noted (Fig.2).

253 Thus AmB would not be able to impair (i) the capacity of *S. mansoni* miracidia to find and
254 penetrate into snail host in aquatic environment, (ii) the capacity of *S. mansoni* miracidia to
255 transform into sporocysts, (iii) the sporocysts growth, development and viability. The present
256 results showed that AmB did not have any direct deleterious effect on miracidia and sporocysts.

257 To go further we looked at the immunomodulatory effect of AmB. In vertebrates AmB was known
258 to activate macrophage oxidative burst by the production of reactive oxygen metabolites (Wilson, et
259 al., 1991, Wolf and Massof, 1990). In invertebrate host of *S. mansoni*, *Biomphalaria glabrata*, the
260 internal defense system is mediated by either humoral and/or cell components (Ataev and Coustau,
261 1999, Bayne, et al., 2001). The most important effectors of immunity in molluscs are the circulating
262 hemocytes. These phagocytic cells are able to distinguish foreign, non-self material, and
263 encapsulate, kill and eliminate invaders such as parasite sporocysts (de Jong-Brink, et al., 2001,
264 Hahn, et al., 2001). Several studies have indicated that reactive oxygen species (ROS), like
265 hydrogen peroxide, produced by hemocytes play a crucial role in the killing of the parasite (Adema,
266 et al., 1994, Bayne, et al., 2001, Dikkeboom, et al., 1988, Hahn, et al., 2001). In the present study
267 we investigated the *in vitro* effect of AmB on *B. glabrata* hemocyte ROS production. ROS were

268 quantified by NBT reduction after hemocytes treatment with AmB alone or in combination with the
269 respiratory burst stimulator PMA. Intracellular ROS production by AmB treated and PMA
270 stimulated hemocytes did not differ from that of untreated/unstimulated control cells (Fig. 2C). It
271 seems that AmB did not affect *B. glabrata* immune effectors. Unlike vertebrates it seems that AmB
272 did not induce immunomodulatory effect in the invertebrate's phagocytic cells and did not activate
273 hemocyte oxidative burst.

274 Decreased prevalence of *S. mansoni* sporocysts after AmB treatment observed in the present paper
275 would thus neither be related to a direct deleterious effect on the parasite's membrane nor to
276 activation of invertebrate host immunity. However, AmB may induce oxidative damage in
277 conjunction with other oxidizing agents (Brajtburg, et al., 1985). Thus we investigated the
278 resistance of Sp1 to H₂O₂ oxidative stress after treatment with AmB. A significant difference was
279 noted between AmB-treated and untreated sporocysts (Fig. 3). This suggests that Sp1 exposed to
280 AmB are less able to respond to oxidative stress. To go further and clarify the influence of AmB on
281 parasite antioxidant activity, we measure the total antioxidant capacity of the sporocysts after
282 treatment with AmB. The results show that AmB treatment causes a decrease of the sporocyst
283 antioxidant capacity in a dose-dependant manner. Living organisms have a large number of
284 antioxidants, including macro and micro molecules, and enzymes that play a central role in
285 preventing oxidative stress. AmB affects the global antioxidant capacity of the parasite and thus
286 directly reduces its ability to respond to oxidative stress.

287 It is known that miracidia and sporocysts use antioxidant molecules and ROS scavengers to protect
288 themselves against hemocyte-mediated cytotoxicity (Bernal, et al., 2006, Connors, et al., 1991,
289 Guillou, et al., 2007, Knudsen, et al., 2005, Perez-Sanchez, et al., 2006, Roger, et al., 2008). If
290 parasite antioxidant molecules were used to overcome AmB oxidant effects, those molecules would
291 not be available and effective against ROS snail host activities. Thus sporocysts would not be able
292 to protect themselves from a second oxidative stress that occurred when sporocysts are confronted
293 by snail hemocytes ROS products (Bayne, 2009, Bayne, et al., 2001, Bender, et al., 2005).

294

295 ACKNOWLEDGMENTS

296 This work was supported by the CNRS. We thank Bernard Dejean, and Anne Rognon, for technical
297 assistance. We are grateful to Dr. Michael Freitag and Dr. Christoph Grunau for their critical
298 reading of the manuscript.

299

300

301 REFERENCES

302

- 303 1. Adema, C. M., van Deutekom-Mulder, E. C., van der Knaap, W. P., and Sminia, T., 1994.
304 Schistosomicidal activities of *Lymnaea stagnalis* haemocytes: the role of oxygen radicals.
305 *Parasitology* 109 (Pt 4), 479-485.
- 306 2. Anderson, R. S., and Brubacher, L. L., 1995. Intracellular superoxide production by
307 quantitative nitroblue tetrazolium reduction. SOS Publications, Fair Haven, NJ, USA.
- 308 3. Ataev, G. L., and Coustau, C., 1999. Cellular response to *Echinostoma caproni* infection in
309 *Biomphalaria glabrata* strains selected for susceptibility/resistance. *Developmental and*
310 *Comparative Immunology* 23, 187-198.
- 311 4. Azzi, A., Cosseau, C., and Grunau, C., 2009. *Schistosoma mansoni*: developmental arrest of
312 miracidia treated with histone deacetylase inhibitors. *Experimental parasitology* 121, 288-
313 291.
- 314 5. Bayne, C. J., 2009. Successful parasitism of vector snail *Biomphalaria glabrata* by the
315 human blood fluke (trematode) *Schistosoma mansoni*: a 2009 assessment. *Molecular and*
316 *biochemical parasitology* 165, 8-18.
- 317 6. Bayne, C. J., Hahn, U. K., and Bender, R. C., 2001. Mechanisms of molluscan host
318 resistance and of parasite strategies for survival. *Parasitology* 123 Suppl, S159-167.
- 319 7. Beccari, T., Mazzolla, R., Constanzi, E., Datti, A., Barluzzi, R., Bistoni, F., and Orlandi,
320 A., 1991. Amphotericin B stimulates secretion of beta-hexosaminidase from mouse adherent
321 spleen cells. *Biochemistry international* 24, 235-241.
- 322 8. Beltran, S., and Boissier, J., 2008. Schistosome monogamy: who, how, and why? *Trends in*
323 *parasitology* 24, 386-391.
- 324 9. Beltran, S., Cezilly, F., and Boissier, J., 2008. Genetic dissimilarity between mates, but not
325 male heterozygosity, influences divorce in schistosomes. *PLoS One* 3, e3328.
- 326 10. Bender, R. C., Bixler, L. M., Lerner, J. P., and Bayne, C. J., 2002. *Schistosoma mansoni*
327 sporocysts in culture: host plasma hemoglobin contributes to in vitro oxidative stress. *The*
328 *Journal of parasitology* 88, 14-18.
- 329 11. Bender, R. C., Broderick, E. J., Goodall, C. P., and Bayne, C. J., 2005. Respiratory burst of
330 *Biomphalaria glabrata* hemocytes: *Schistosoma mansoni*-resistant snails produce more
331 extracellular H₂O₂ than susceptible snails. *Journal of Parasitology* 91, 275-279.
- 332 12. Bernal, D., Carpena, I., Espert, A. M., De la Rubia, J. E., Esteban, J. G., Toledo, R., and
333 Marcilla, A., 2006. Identification of proteins in excretory/secretory extracts of *Echinostoma*
334 *friedi* (Trematoda) from chronic and acute infections. *Proteomics* 6, 2835-2843.

- 335 13. Bouchut, A., Roger, E., Gourbal, B., Grunau, C., Coustau, C., and Mitta, G., 2008. The
336 compatibility polymorphism in invertebrate host/trematodes interactions: research of
337 molecular determinants. *Parasite* 15, 304-309.
- 338 14. Bouchut, A., Sautiere, P. E., Coustau, C., and Mitta, G., 2006. Compatibility in the
339 *Biomphalaria glabrata*/*Echinostoma caproni* model: Potential involvement of proteins from
340 hemocytes revealed by a proteomic approach. *Acta tropica* 98, 234-246.
- 341 15. Brajtburg, J., Elberg, S., Schwartz, D. R., Vertut-Croquin, A., Schlessinger, D., Kobayashi,
342 G. S., and Medoff, G., 1985. Involvement of oxidative damage in erythrocyte lysis induced
343 by amphotericin B. *Antimicrobial agents and chemotherapy* 27, 172-176.
- 344 16. Chernin, E., 1963. Observations on hearts explanted in vitro from the snail *Australorbis*
345 *glabratus*. *The Journal of parasitology* 49, 353-364.
- 346 17. Chitsulo, L., Loverde, P., and Engels, D., 2004. Schistosomiasis. *Nature Review*
347 *Microbiology* 2, 12-13.
- 348 18. Connors, V. A., Lodes, M. J., and Yoshino, T. P., 1991. Identification of a *Schistosoma*
349 *mansoni* sporocyst excretory-secretory antioxidant molecule and its effect on superoxide
350 production by *Biomphalaria glabrata* hemocytes. *Journal of Invertebrate Pathology* 58, 387-
351 395.
- 352 19. Coustau, C., and Yoshino, T. P., 2000. Flukes without snails: advances in the in vitro
353 cultivation of intramolluscan stages of trematodes. *Experimental Parasitology* 94, 62-66.
- 354 20. Cruz, F. S., Marr, J. J., and Berens, R. L., 1980. Prevention of transfusion-induced Chagas'
355 disease by amphotericin B. *The American journal of tropical medicine and hygiene* 29, 761-
356 765.
- 357 21. de Jong-Brink, M., Bergamin-Sassen, M., and Solis Soto, M., 2001. Multiple strategies of
358 schistosomes to meet their requirements in the intermediate snail host. *Parasitology* 123
359 Suppl, S129-141.
- 360 22. Dikkeboom, R., Bayne, C. J., van der Knaap, W. P., and Tijnagel, J. M., 1988. Possible role
361 of reactive forms of oxygen in in vitro killing of *Schistosoma mansoni* sporocysts by
362 hemocytes of *Lymnaea stagnalis*. *Parasitology Research* 75, 148-154.
- 363 23. Gryseels, B., Polman, K., Clerinx, J., and Kestens, L., 2006. Human schistosomiasis. *Lancet*
364 368, 1106-1118.
- 365 24. Guillou, F., Roger, E., Mone, Y., Rognon, A., Grunau, C., Theron, A., Mitta, G., Coustau,
366 C., and Gourbal, B. E., 2007. Excretory-secretory proteome of larval *Schistosoma mansoni*
367 and *Echinostoma caproni*, two parasites of *Biomphalaria glabrata*. *Molecular and*
368 *biochemical parasitology* 155, 45-56.
- 369 25. Guillou, F., Roger, E., Mone, Y., Rognon, A., Grunau, C., Theron, A., Mitta, G., Coustau,
370 C., and Gourbal, B. E., 2007. Excretory-secretory proteome of larval *Schistosoma mansoni*
371 and *Echinostoma caproni*, two parasites of *Biomphalaria glabrata*. *Molecular and*
372 *Biochemical Parasitology* 155, 45-56.
- 373 26. Hahn, U. K., Bender, R. C., and Bayne, C. J., 2001. Involvement of nitric oxide in killing of
374 *Schistosoma mansoni* sporocysts by hemocytes from resistant *Biomphalaria glabrata*.
375 *Journal of Parasitology* 87, 778-785.
- 376 27. HsuChen, C. C., and Feingold, D. S., 1973. Polyene antibiotic action on lecithin liposomes:
377 effect of cholesterol and fatty acyl chains. *Biochemical and biophysical research*
378 *communications* 51, 972-978.
- 379 28. HsuChen, C. C., and Feingold, D. S., 1973. Selective membrane toxicity of the polyene
380 antibiotics: studies on lecithin membrane models (liposomes). *Antimicrobial agents and*
381 *chemotherapy* 4, 309-315.
- 382 29. Knudsen, G. M., Medzihradzky, K. F., Lim, K. C., Hansell, E., and McKerrow, J. H., 2005.
383 Proteomic analysis of *Schistosoma mansoni* cercarial secretions. *Molecular and Cellular*
384 *Proteomics* 4, 1862-1875.
- 385 30. Kuhlmann, I., 1995. The prophylactic use of antibiotics in cell culture. *Cytotechnology* 19,
386 95-105.

- 387 31. Kumar, S., and Chakrabarti, R., 2000. Amphotericin B both inhibits and enhances T-cell
388 proliferation: inhibitory effect is mediated through H₂O₂ production via cyclooxygenase
389 pathway by macrophages. *Journal of cellular biochemistry* 77, 361-371.
- 390 32. Lachaud, L., Bourgeois, N., Plourde, M., Leprohon, P., Bastien, P., and Ouellette, M., 2009.
391 Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in
392 patients coinfecting with HIV type 1 and *Leishmania infantum*. *Clinical Infectious Diseases*
393 48, e16-22.
- 394 33. Little, J. R., Plut, E. J., Kotler-Brajtburg, J., Medoff, G., and Kobayashi, G. S., 1978.
395 Relationship between the antibiotic and immunoadjuvant effects of amphotericin B methyl
396 ester. *Immunochemistry* 15, 219-224.
- 397 34. Mattos, A. C., Kusel, J. R., Pimenta, P. F., and Coelho, P. M., 2006. Activity of praziquantel
398 on in vitro transformed *Schistosoma mansoni* sporocysts. *Memorias do Instituto Oswaldo*
399 *Cruz* 101 Suppl 1, 283-287.
- 400 35. Olds, G. R., Stewart, S. J., and Ellner, J. J., 1981. Amphotericin B-induced resistance to
401 *Schistosoma mansoni*. *Journal of Immunology* 126, 1667-1670.
- 402 36. Perez-Sanchez, R., Ramajo-Hernandez, A., Ramajo-Martin, V., and Oleaga, A., 2006.
403 Proteomic analysis of the tegument and excretory-secretory products of adult *Schistosoma*
404 *bovis* worms. *Proteomics* 6 Suppl 1, S226-236.
- 405 37. Reuter, S., Merkle, M., Brehm, K., Kern, P., and Manfras, B., 2003. Effect of amphotericin
406 B on larval growth of *Echinococcus multilocularis*. *Antimicrobial agents and chemotherapy*
407 47, 620-625.
- 408 38. Roger, E., Gourbal, B., Grunau, C., Pierce, R. J., Galinier, R., and Mitta, G., 2008.
409 Expression analysis of highly polymorphic mucin proteins (Sm PoMuc) from the parasite
410 *Schistosoma mansoni*. *Molecular and biochemical parasitology* 157, 217-227.
- 411 39. Roger, E., Grunau, C., Pierce, R. J., Hirai, H., Gourbal, B., Galinier, R., Emans, R., Cesari,
412 I. M., Cosseau, C., and Mitta, G., 2008. Controlled Chaos of Polymorphic Mucins in a
413 Metazoan Parasite (*Schistosoma mansoni*) Interacting with Its Invertebrate Host
414 (*Biomphalaria glabrata*). *PLoS neglected tropical diseases* 2, e330.
- 415 40. Roger, E., Mitta, G., Mone, Y., Bouchut, A., Rognon, A., Grunau, C., Boissier, J., Theron,
416 A., and Gourbal, B. E., 2008. Molecular determinants of compatibility polymorphism in the
417 *Biomphalaria glabrata*/*Schistosoma mansoni* model: new candidates identified by a global
418 comparative proteomics approach. *Molecular and biochemical parasitology* 157, 205-216.
- 419 41. Smyth, J. D., 1990. *In vitro* cultivation of parasitic helminths. CRC, Boca Raton.
- 420 42. Steinauer, M. L., 2009. The sex lives of parasites: investigating the mating system and
421 mechanisms of sexual selection of the human pathogen *Schistosoma mansoni*. *International*
422 *journal for parasitology* 39, 1157-1163.
- 423 43. Theron, A., Coustau, C., Rognon, A., Gourbiere, S., and Blouin, M. S., 2008. Effects of
424 laboratory culture on compatibility between snails and schistosomes. *Parasitology* 135,
425 1179-1188.
- 426 44. Thomas, M. Z., Medoff, G., and Kobayashi, G. S., 1973. Changes in murine resistance to
427 *Listeria monocytogenes* infection induced by amphotericin B. *The Journal of infectious*
428 *diseases* 127, 373-377.
- 429 45. Wilson, E., Thorson, L., and Speert, D. P., 1991. Enhancement of macrophage superoxide
430 anion production by amphotericin B. *Antimicrobial agents and chemotherapy* 35, 796-800.
- 431 46. Wolf, J. E., and Massof, S. E., 1990. *In vivo* activation of macrophage oxidative burst
432 activity by cytokines and amphotericin B. *Infection and immunity* 58, 1296-1300.
- 433
434
435

436 Adema C.M., van Deutekom-Mulder E.C., van der Knaap W.P. & Sminia T. (1994)
437 Schistosomicidal activities of *Lymnaea stagnalis* haemocytes: the role of oxygen radicals.
438 *Parasitology*, 109 (Pt 4), 479-85

439 Anderson R.S. & Brubacher L.L. (1995) Intracellular superoxide production by quantitative
440 nitroblue tetrazolium reduction. SOS Publications, Fair Haven, NJ, USA.

441 Ataev G.L. & Coustau C. (1999) Cellular response to *Echinostoma caproni* infection in
442 *Biomphalaria glabrata* strains selected for susceptibility/resistance. *Dev Comp Immunol*, 23, 187-98

443 Azzi A., Cosseau C. & Grunau C. (2009) *Schistosoma mansoni*: developmental arrest of miracidia
444 treated with histone deacetylase inhibitors. *Exp Parasitol*, 121, 288-91

445 Bayne C.J. (2009) Successful parasitism of vector snail *Biomphalaria glabrata* by the human blood
446 fluke (trematode) *Schistosoma mansoni*: a 2009 assessment. *Mol Biochem Parasitol*, 165, 8-18

447 Bayne C.J., Hahn U.K. & Bender R.C. (2001) Mechanisms of molluscan host resistance and of
448 parasite strategies for survival. *Parasitology*, 123 Suppl, S159-67

449 Beccari T., Mazzolla R., Constanzi E., Datti A., Barluzzi R., Bistoni F. & Orlandi A. (1991)
450 Amphotericin B stimulates secretion of beta-hexosaminidase from mouse adherent spleen cells.
451 *Biochem Int*, 24, 235-41

452 Beltran S. & Boissier J. (2008) Schistosome monogamy: who, how, and why? *Trends Parasitol*, 24,
453 386-91

454 Beltran S., Cezilly F. & Boissier J. (2008) Genetic dissimilarity between mates, but not male
455 heterozygosity, influences divorce in schistosomes. *PLoS One*, 3, e3328

456 Bender R.C., Bixler L.M., Lerner J.P. & Bayne C.J. (2002) *Schistosoma mansoni* sporocysts in
457 culture: host plasma hemoglobin contributes to in vitro oxidative stress. *J Parasitol*, 88, 14-8

458 Bender R.C., Broderick E.J., Goodall C.P. & Bayne C.J. (2005) Respiratory burst of *Biomphalaria*
459 *glabrata* hemocytes: *Schistosoma mansoni*-resistant snails produce more extracellular H₂O₂ than
460 susceptible snails. *J Parasitol*, 91, 275-9

461 Bernal D., Carpena I., Espert A.M., De la Rubia J.E., Esteban J.G., Toledo R. & Marcilla A. (2006)
462 Identification of proteins in excretory/secretory extracts of *Echinostoma friedi* (Trematoda) from
463 chronic and acute infections. *Proteomics*, 6, 2835-43

464 Bouchut A., Roger E., Gourbal B., Grunau C., Coustau C. & Mitta G. (2008) The compatibility
465 polymorphism in invertebrate host/trematodes interactions: research of molecular determinants.
466 *Parasite*, 15, 304-9

467 Bouchut A., Sautiere P.E., Coustau C. & Mitta G. (2006) Compatibility in the *Biomphalaria*
468 *glabrata*/*Echinostoma caproni* model: Potential involvement of proteins from hemocytes revealed
469 by a proteomic approach. *Acta Trop*, 98, 234-46

470 Brajtburg J., Elberg S., Schwartz D.R., Vertut-Croquin A., Schlessinger D., Kobayashi G.S. &
471 Medoff G. (1985) Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B.
472 *Antimicrob Agents Chemother*, 27, 172-6

473 Chernin E. (1963) Observations on hearts explanted in vitro from the snail *Australorbis glabratus*. *J*
474 *Parasitol*, 49, 353-64

475 Chitsulo L., Loverde P. & Engels D. (2004) Schistosomiasis. *Nat Rev Microbiol*, 2, 12-3

476 Connors V.A., Lodes M.J. & Yoshino T.P. (1991) Identification of a *Schistosoma mansoni*
477 sporocyst excretory-secretory antioxidant molecule and its effect on superoxide production by
478 *Biomphalaria glabrata* hemocytes. *J Invertebr Pathol*, 58, 387-95

479 Coustau C. & Yoshino T.P. (2000) Flukes without snails: advances in the in vitro cultivation of
480 intramolluscan stages of trematodes. *Exp Parasitol*, 94, 62-6

481 Cruz F.S., Marr J.J. & Berens R.L. (1980) Prevention of transfusion-induced Chagas' disease by
482 amphotericin B. *Am J Trop Med Hyg*, 29, 761-5

483 de Jong-Brink M., Bergamin-Sassen M. & Solis Soto M. (2001) Multiple strategies of schistosomes
484 to meet their requirements in the intermediate snail host. *Parasitology*, 123 Suppl, S129-41

485 Dikkeboom R., Bayne C.J., van der Knaap W.P. & Tijnagel J.M. (1988) Possible role of reactive
486 forms of oxygen in in vitro killing of *Schistosoma mansoni* sporocysts by hemocytes of *Lymnaea*
487 *stagnalis*. *Parasitol Res*, 75, 148-54

488 Gryseels B., Polman K., Clerinx J. & Kestens L. (2006) Human schistosomiasis. *Lancet*, 368, 1106-
489 18

490 Guillou F., Roger E., Mone Y., Rognon A., Grunau C., Theron A., Mitta G., Coustau C. & Gourbal
491 B.E. (2007) Excretory-secretory proteome of larval *Schistosoma mansoni* and *Echinostoma caproni*,
492 two parasites of *Biomphalaria glabrata*. *Mol Biochem Parasitol*, 155, 45-56

493 Hahn U.K., Bender R.C. & Bayne C.J. (2001) Involvement of nitric oxide in killing of *Schistosoma*
494 *mansoni* sporocysts by hemocytes from resistant *Biomphalaria glabrata*. *J Parasitol*, 87, 778-85

495 HsuChen C.C. & Feingold D.S. (1973a) Polyene antibiotic action on lecithin liposomes: effect of
496 cholesterol and fatty acyl chains. *Biochem Biophys Res Commun*, 51, 972-8

497 Hsuchen C.C. & Feingold D.S. (1973b) Selective membrane toxicity of the polyene antibiotics:
498 studies on lecithin membrane models (liposomes). *Antimicrob Agents Chemother*, 4, 309-15

499 Knudsen G.M., Medzihradzky K.F., Lim K.C., Hansell E. & McKerrow J.H. (2005) Proteomic
500 analysis of *Schistosoma mansoni* cercarial secretions. *Mol Cell Proteomics*, 4, 1862-75

501 Kuhlmann I. (1995) The prophylactic use of antibiotics in cell culture. *Cytotechnology*, 19, 95-105

502 Kumar S. & Chakrabarti R. (2000) Amphotericin B both inhibits and enhances T-cell proliferation:
503 inhibitory effect is mediated through H₂O₂ production via cyclooxygenase pathway by
504 macrophages. *J Cell Biochem*, 77, 361-71

505 Lachaud L., Bourgeois N., Plourde M., Leprohon P., Bastien P. & Ouellette M. (2009) Parasite
506 susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients
507 coinfecting with HIV type 1 and *Leishmania infantum*. *Clin Infect Dis*, 48, e16-22

508 Little J.R., Plut E.J., Kotler-Brajtburg J., Medoff G. & Kobayashi G.S. (1978) Relationship between
509 the antibiotic and immunoadjuvant effects of amphotericin B methyl ester. *Immunochemistry*, 15,
510 219-24

511 Mattos A.C., Kusel J.R., Pimenta P.F. & Coelho P.M. (2006) Activity of praziquantel on in vitro
512 transformed *Schistosoma mansoni* sporocysts. *Mem Inst Oswaldo Cruz*, 101 Suppl 1, 283-7

513 Olds G.R., Stewart S.J. & Ellner J.J. (1981) Amphotericin B-induced resistance to *Schistosoma*
514 *mansoni*. *J Immunol*, 126, 1667-70

515 Perez-Sanchez R., Ramajo-Hernandez A., Ramajo-Martin V. & Oleaga A. (2006) Proteomic
516 analysis of the tegument and excretory-secretory products of adult *Schistosoma bovis* worms.
517 *Proteomics*, 6 Suppl 1, S226-36

518 Reuter S., Merkle M., Brehm K., Kern P. & Manfras B. (2003) Effect of amphotericin B on larval
519 growth of *Echinococcus multilocularis*. *Antimicrob Agents Chemother*, 47, 620-5

520 Roger E., Gourbal B., Grunau C., Pierce R.J., Galinier R. & Mitta G. (2008a) Expression analysis
521 of highly polymorphic mucin proteins (Sm PoMuc) from the parasite *Schistosoma mansoni*. *Mol*
522 *Biochem Parasitol*, 157, 217-27

523 Roger E., Grunau C., Pierce R.J., Hirai H., Gourbal B., Galinier R., Emans R., Cesari I.M., Cosseau
524 C. & Mitta G. (2008b) Controlled Chaos of Polymorphic Mucins in a Metazoan Parasite
525 (*Schistosoma mansoni*) Interacting with Its Invertebrate Host (*Biomphalaria glabrata*). *PLoS Negl*
526 *Trop Dis*, 2, e330

527 Roger E., Mitta G., Mone Y., Bouchut A., Rognon A., Grunau C., Boissier J., Theron A. & Gourbal
528 B.E. (2008c) Molecular determinants of compatibility polymorphism in the *Biomphalaria*
529 *glabrata*/*Schistosoma mansoni* model: new candidates identified by a global comparative
530 proteomics approach. *Mol Biochem Parasitol*, 157, 205-16

531 Smyth J.D. (1990) *In vitro* cultivation of parasitic helminths. CRC, Boca Raton.

532 Steinauer M.L. (2009) The sex lives of parasites: investigating the mating system and mechanisms
533 of sexual selection of the human pathogen *Schistosoma mansoni*. *Int J Parasitol*, 39, 1157-63

534 Theron A., Coustau C., Rognon A., Gourbiere S. & Blouin M.S. (2008) Effects of laboratory
535 culture on compatibility between snails and schistosomes. *Parasitology*, 135, 1179-88

536 Thomas M.Z., Medoff G. & Kobayashi G.S. (1973) Changes in murine resistance to *Listeria*
537 *monocytogenes* infection induced by amphotericin B. *J Infect Dis*, 127, 373-7

538 Wilson E., Thorson L. & Speert D.P. (1991) Enhancement of macrophage superoxide anion
539 production by amphotericin B. *Antimicrob Agents Chemother*, 35, 796-800

540 Wolf J.E. & Massof S.E. (1990) In vivo activation of macrophage oxidative burst activity by
541 cytokines and amphotericin B. *Infect Immun*, 58, 1296-300

542

543 **Legends to figures:**

544 **Figure 1:**

545 Prevalence and abundance of *S. mansoni* sporocysts in *B. glabrata* exposed to miracidia
546 treated with different antimicrobial substances. The snails were individually exposed to 10
547 miracidia treated either by 1X AM, 100U/ml PnG, 10mg/ml StrS, or 0.25µg/ml AmB. The control
548 was untreated miracidia. The asterisks indicate treatment for which the decrease of prevalence is
549 significant ($p < 0.05$).

550

551 **Figure 2**

552 Influence of the antimicrobial substances on *S. mansoni* and *B. glabrata* behavioral and
553 physiological traits. (A) Linear swimming speed of miracidia exposed to 1X AM, 100U/ml PnG,
554 10mg/ml StrS, or 0.25µg/ml AmB. (B.1) Viability % of sporocysts after 24 hours in CBSS medium
555 containing a mixture of 100U/ml PnG and 10mg/ml StrS used as control or 1X AM or 0.25µg/ml
556 AmB. (B.2) *S. mansoni* miracidia and cultivated sporocysts in presence or absence of 0.25µg/ml
557 AmB. Miracidia and sporocysts were exposed to AmB for 3 hours and 24 hours respectively. The
558 detached ciliated plates in the sporocysts culture were indicated with black arrows. Scale bars are 35
559 µm. (C) AmB (0.25µg/ml) effect on ROS production by *B. glabrata* hemocytes stimulated or not by
560 PMA. The ROS production was assessed by the reduction of nitroblue tetrazolium measured
561 spectrophotometrically at 620 nm.

562

563 **Figure 3**

564 Sporocyst viability 4 hours after exposure to different H₂O₂ concentrations. The sporocysts
565 were treated with AmB (0.25µg/ml) for 24 hours in CBSS medium or untreated. The asterisk
566 indicate significant difference ($p < 0.05$) of viability between AmB treated and untreated sporocysts.

567

568 **Figure 4:**

569 Total antioxidant capacity of sporocysts exposed to different concentrations of AmB. The
570 sporocysts were treated with AmB (0.25; 0.5; 1.25 μ g/ml) for 24 hours in CBSS medium or
571 untreated. The asterisk indicate significant difference ($p < 0.05$) of antioxidant concentration between
572 AmB treated and untreated sporocysts.

573

574

575

576

Figure 1

577

578

579

580

581

582

583

584

585

586

587

588


589

590

591

592

593



594 **Figure 2**

595

596


597

598

599

600

601



602

B.1

603


604

605


606

607

608



B.2



609

610

611

612

613

614


615

616

C

617

618



619 Figure 3

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636


637

638

639

640

641



642

Figure 4

643

644

